Search

The second in an ongoing series led by Dr. Mrinal Gounder of MSK and Dr. Sewanti Limaye of Sir HN Reliance Foundation Hospital in Mumbai, this tumor board focused on the BRAF pathway.

… International Precision Oncology Tumor Board - Targeting the BRAF Pathway: MSK & Sir HN Reliance Foundation Hospital The second in an ongoing series led by Dr. Mrinal Gounder from MSK and Dr. Sewanti Limaye of Sir HN Reliance Foundation Hospital in Mumbai, this tumor board focused on the BRAF pathway

… Job Title Research Fellow Education MD, SUNY Downstate College of Medicine, Brooklyn, NY Email [email protected] Publications Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials.  Pharmacol Ther . 2025;266:108763. Tidjani A, Bhat

… Job Title Research Technician Email [email protected]

The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.

… Tuesday, August 22, 2023 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook. This visionary

… Job Title Assistant Attending Email [email protected]

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.

… Saturday, June 1, 2013 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma , according to new Memorial Sloan Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of

Director, Clinical Scientist at G1 Therapeutics, Inc, Research Triangle Park, NC

… Job Title Director, Clinical Scientist at G1 Therapeutics, Inc, Research Triangle Park, NC Education California State University, Northridge Degree PhD Dissertation IL-6/Stat3 Mediated Down-Regulation of Estrogen Receptor Alpha (ER) Expression in Breast Cancer (2014) Start Year 2007 End Year 2014 Publications

MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.

… Wednesday, February 22, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, published in Nature on February 22, uncover facets

Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.

… Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma. Figure 1 Poxviruses